This Welsh company is playing a part in the fight against respiratory, brain and cardiovascular disease. Co-founded by chief executive Andrew Williams and David Greenwood, Marix uses digital monitoring technology to analyse drug safety and efficacy. Contracts with European, American and Japanese pharmaceutical companies have boosted sales 82% a year from £908,000 in 2003 to £3m in 2005.

This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.

Company details
Year2006
Rank39
CompanyMarix Drug Development
ActivityClinical drug developer
LocationSouth Wales
Average 3 year sales growth81.81%
Latest sales £000s3,003
Staff30
Founded2001
Websitewww.marix.co.uk

If applicable:

* supplied by company † annualised figure